Patents by Inventor Mary Melissa McFarland

Mary Melissa McFarland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USP19 INHIBITORS FOR USE IN THERAPY
    Publication number: 20220016115
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: James Samuel Shane ROUNTREE, Peter HEWITT, Mary Melissa MCFARLAND, Frank BURKAMP, Christina BELL, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYKA, Aaron CRANSTON, Xavier JACQ, Lauren PROCTOR
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20220002264
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 6, 2022
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • Pharmaceutical compounds
    Patent number: 11053213
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 6, 2021
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Peter Hewitt, Mary Melissa McFarland, James Samuel Shane Rountree, Frank Burkamp, Christina Bell, Lauren Proctor, Matthew Duncan Helm, Colin O'Dowd, Timothy Harrison
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20190233394
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 26, 2017
    Publication date: August 1, 2019
    Applicant: Almac Discovery Limited
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • AKT / PKB INHIBITORS
    Publication number: 20120309739
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: November 3, 2010
    Publication date: December 6, 2012
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Mark Peter Bell, Colin Roderick O'Dowd, James Samuel Shane Rountree, Graham Peter Trevitt, Timothy Harrison, Mary Melissa McFarland